Kudos to Prostate Cancer Foundation for an excellent meeting and for the opportunity to kick off the 9th annual #GenderEquityNetworkingInitiative #womeninSTEM #pcfretreat24 Andrea Miyahira

OK...MegaThread time. #AUO24 is almost here! Join us November 1-2 at the Bethesda Marriott for MedStar’s Advances in Urologic Oncology Conference! Not too late to register online (MedStarHealth.org/AdvancesInUrol…) or at the door. Dive into sessions on prostate, kidney, bladder, and

From our neighbors at the great NIH Clinical Center, Dr. Fatima Karzai Fatima Karzai, M.D. will cover what to do with de-novo metastatic PCA and CRPC!

Come out to this great meeting! Keith Kowalczyk, MD MedStar Health

Indeed

Back in Boston. Happy to be able to talk all things BRCA at the Center for BRCA & Related Genes Annual Scientific Symposium Dana-Farber #BRCA #itsinthegenes

Fatima Karzai, M.D. is next on the agenda, presenting on patient populations that have a high risk of developing prostate cancer and how to risk-stratify

I love when audience members nod and smile at me when I give a talk. I see you! #womeninmedicine #WomenInSTEM

Love this group! #superstars #womeninSTEM

Hola Bogota! Excited to be apart of the #PCF Visiting Professorship to exchange ideas to improve patient health Prostate Cancer Foundation PCF Science

Happy Holidays from your friends National Cancer Institute NIH NIH Clinical Center

#PARP inhibitors in #ProstateCancer will again take center stage at #GU25 ASCO Here is refresher on some thoughts of the earlier data in #mCRPC @vanderweelemd Heather H. Cheng Fatima Karzai, M.D. UroToday.com OncoAlert ascopubs.org/doi/10.1200/JC…

Never Ravi A Madan M.D.

Great to be at the #CPDRRetreat Center for Prostate Disease Research EllisLab_ Ayesha Shafi, PhD

Come see me Chair the 🔥session at #ASCO25 ASCO with a fantastic line up

"The human heart is a miraculous organ. It supplies itself before it serves others, a lesson we all could live by.” Dr. Helen Taussig

Insert pic of me on a plane here 🙂

The most practice changing trial from #ASCO25 is now live on NEJM .If this was a drug, this would be approved today. Globally relevant and low-cost intervention that is not only delaying relapse but actually improving survival. Perfect case example of a #cancergroundshot trial.

Happening now! Come and see me!

Excited to share our work performed at National Cancer Institute addressing needs of rare hereditary kidney cancer through bench to bedside work Bevacizumab + erlotinib for #HLRCC assoc RCC 📍Response rate 72% 📍mPFS 21.1 mo Thanks to the patients who supported the study! nejm.org/doi/full/10.10…